Clinical trials: Obese Adults
Weight Loss
A Study to Assess the Effects of Freshly Fit Meals on Body Weight and Wellness in Overweight and Obese Adults
The primary objective of this trial is to examine the weight-loss efficacy of Freshly Fit meals, as well as body composition, waist/hip circumference, metabolic markers, and quality of life in overweight and obese adults.
- Trial name
- NCT04793113
- Testing
- FreshlyFit Meals
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Freshly, Inc.
Type 2 Diabetes, Obesity
A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity
This is a multicenter, randomized, Open-label Phase 3 clinical study comparing the efficacy and safety of IBI362 6 mg OW versus Semalgutide 1 mg OW in obese(BMI≥28kg/m2) early T2D subjects.
- Trial name
- NCT06184568
- Testing
- IBI362, Semaglutide
- Where
- China
- Volunteers
- 349 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Obesity or Overweight
A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
The study will evaluate how well AZD6234 works and how safe it is in adults with excess weight or obesity. Efficacy of AZD6234 will be compared to placebo in percent body weight change from baseline at 68 weeks of treatment
- Trial name
- SELENE 1 (NCT07784725)
- Testing
- Lenbelintide
- Where
- 220 sites in United States, Argentina and 14 more
- Volunteers
- 2,500 people
- Sponsor
- AstraZeneca
Healthy Volunteers;, Obese, Otherwise Healthy Volunteers
A Study to Examine the, Safety, Tolerability and Pharmacokinetics Co-Administered Baclofen and Memantine in Obese and Lean, Otherwise Healthy Adults
The purpose of this study is to investigate the safety, tolerability and pharmacokinetics of a predefined dose range of co-administered Baclofen and Memantine in non-obese (Part A) and obese (Part B), otherwise healthy subjects.
- Trial name
- NCT02001584
- Testing
- Baclofen, Memantine
- Where
- United Kingdom
- Sponsor
- Gedeon Richter Plc.
Binge Eating, Obesity
Feasibility of a Digital Therapeutic for Adults With Binge Eating and Obesity
The primary objective of this study is to test the feasibility of a digital therapeutic to address comorbid binge eating and obesity in adults.
- Trial name
- NCT06454123
- Testing
- OTX-401
- Volunteers
- 30 people
- Sponsor
- Oui Therapeutics, Inc.
Obesity, Diabetes Mellitus, Type 2
A Study of the Efficacy and Safety of Topiramate in the Treatment fo Obese, Type 2 Diabetic Patients Treated With Metformin
The purpose of this study is to compare the efficacy (in terms of weight and hemoglobin type A1c [HbA1c]) and safety of topiramate (96 milligrams[mg] or 192 mg daily) with placebo in the treatment of obesity in Type 2 diabetic…
- Conditions
- Obesity, Diabetes Mellitus, Type 2, Diabetes Mellitus, Adult-Onset
- Trial name
- NCT00231660
- Testing
- topiramate
- Volunteers
- 211 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Obesity
Safety, Toleration and Pharmacokinetics of Single Intravenous Doses of Peptide YY in Overweight Adults
The purpose of this trial is to evaluate the safety and tolerability of single escalating doses of Peptide YY3-36 and to determine effects on food intake and serum hormones when administered by intravenous infusion to otherwise…
- Trial name
- NCT00331175
- Testing
- Peptide YY3-36
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy Subjects;Overweight or Obesity
A Phase 1 Study of GZC8072 Tablets Following a Single Dose in Healthy Study Participants and Multiple Doses in Obese/Overweight Study Participants
This trial is conducted in China. This study plans to include 2 parts, i.e., a single-dose study and a multiple-dose study: The single-dose study will be conducted in healthy adult participants to evaluate the safety…
- Trial name
- NCT07784699
- Testing
- GZC8072 Tablets
- Where
- China
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Gan & Lee Pharmaceuticals.
Obesity Type 2 Diabetes Mellitus, Obese Adults
Clinical Research Trial to Study Insulin Sensitivity Using Automated Glucose Clamp Technology
This trial will establish fully-automated glucose clamping using state-of-the-art technology (ClampArt®) at a US based clinical research center
- Conditions
- Obesity Type 2 Diabetes Mellitus, Obese Adults, Type 2 Diabetes Mellitus
- Trial name
- NCT07913698
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Profil Institut für Stoffwechselforschung GmbH
Obesity, Metabolic Disease
Xla1 Christensenella Minuta, Phase I, Randomized, Partially Placebo-controlled Double-blind Protocol, Evaluating Safety, Tolerability and Impact on the Gut Microbiota in Healthy Volunteers, Overweight and Obese Adults
Xla1 Christensenella minuta, phase I, randomized, placebo-controlled double-blind protocol, evaluating safety, tolerability and impact on the gut microbiota in healthy volunteers, overweight and obese adults.
- Trial name
- CAUSALITY (NCT04663139)
- Testing
- Xla1
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- YSOPIA Bioscience
Obesity, Overweight or Obesity
A Phase 2b Study to Examine the Safety and Efficacy of Once-Weekly MET097 in Adults With Obesity or Overweight
This study is designed to test how well MET097, an active drug, works to treat individuals with obesity or overweight when compared to placebo. MET097 or placebo will be given to individuals weekly for 28 weeks.
- Trial name
- VESPER-1 (NCT06712836)
- Testing
- MET097
- Where
- 2 sites in United States
- Volunteers
- 239 people
- Sponsor
- Pfizer
Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes)
The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function.
- Trial name
- NCT06383390
- Testing
- Retatrutide
- Where
- 742 sites in United States, Argentina and 25 more
- Volunteers
- 10,000 people
- Sponsor
- Eli Lilly and Company
Genetic Disorder, Prader-Willi Syndrome
Bioequivalence of Two Somatropin Products (Norditropin® Versus Genotropin®) in Healthy Adult Volunteers
This trial is conducted in United States of America (USA). The aim of this trial is to examine the bioequivalence of Norditropin® versus Genotropin® in healthy adult volunteers.
- Conditions
- Genetic Disorder, Prader-Willi Syndrome, Growth Disorder, Idiopathic Short Stature
- Trial name
- NCT01401244
- Testing
- somatropin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Novo Nordisk A/S
Antipsychotic-induced Weight Gain (AIWG)
A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Obese Adult Patients With Schizophrenia While Taking Antipsychotic Medications (GRATITUDE II)
This Phase 2, double-blind, placebo-controlled, randomized study is to assess the safety, efficacy, and pharmacokinetics (PK) of miricorilant (CORT118335) in obese patients with schizophrenia treated with antipsychotic…
- Trial name
- NCT04524403
- Testing
- Miricorlilant
- Where
- 40 sites in United States
- Volunteers
- 150 people
- Sponsor
- Corcept Therapeutics
Obesity
A Study to Learn About Safety and Effects of Once-weekly Treatment With Berobenatide in Adults With Obesity Disease in Japan (VESPER-JW)
The purpose of this clinical study is to learn about safety and effects of berobenatide (PF-08653944) in adults with obesity disease, a condition where a person has too much body fat, which can harm their health and increase the…
- Trial name
- NCT07794761
- Testing
- Berobenatide
- Where
- 34 sites in Japan
- Volunteers
- 180 people
- Sponsor
- Pfizer
Overweight, Obesity
A Research Study Investigating NNC0247-0829 for Weight Management in People With Overweight or Obesity
This study looks at NNC0247-0829 (a potential new medicine) for weight management in people with overweight or obesity. The study looks at how NNC0247-0829 works in the body.
- Trial name
- NCT04010786
- Testing
- NNC0247-0829
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- Novo Nordisk A/S
Obesity, Overweight
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various investigational interventions for chronic weight management with…
- Trial name
- NCT06143956
- Testing
- LY3305677, LY3841136, Tirzepatide
- Where
- 57 sites in United States, Argentina
- Volunteers
- 1,481 people
- Sponsor
- Eli Lilly and Company
Psoriasis, Obesity
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
The main purpose of this study is to demonstrate that when participants with moderate to severe plaque psoriasis and obesity or overweight in the presence of at least 1 weight-related comorbid condition receive ixekizumab and…
- Trial name
- TOGETHER-PsO (NCT06588283)
- Testing
- Ixekizumab, Tirzepatide
- Where
- 72 sites in United States, Puerto Rico
- Volunteers
- 281 people
- Sponsor
- Eli Lilly and Company
Bioelectrical Impedance Measurement of Healthy Adults
Generation of Prediction Equations to Analyze Body Composition of Obese Adults Based on BIA
The study was based on the clinical trial BCA-01 (NCT01368640) "Generation of prediction equations to analyze body composition of adults based on Bioelectrical Impedance Analysis (BIA)" and implicates an extension of the study…
- Trial name
- NCT03779932
- Where
- Germany
- Volunteers
- 38 people
- Sponsor
- Seca GmbH & Co. Kg.
Obesity, Overweight
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, Type 2 Diabetes, and Increased Cardiovascular Risk
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with a placebo in participants with obesity or overweight, type 2 diabetes, and increased cardiovascular risk.
- Conditions
- Obesity, Overweight, Cardiovascular Diseases, Diabetes Mellitus, Type 2
- Trial name
- ENLIGHTEN-10 (NCT07900633)
- Testing
- Eloralintide
- Where
- 309 sites in United States, Argentina and 19 more
- Volunteers
- 3,000 people
- Sponsor
- Eli Lilly and Company